GO:0005000 vasopressin receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005000 (vasopressin receptor activity) is a molecular function defined as combining with vasopressin to initiate a change in cell activity.
• The term covers G-protein-coupled receptors that bind the nonapeptide vasopressin (AVP) and its synthetic analogs, including V1a, V1b and V2 subtypes.
• Vasopressin receptor signaling is central to water homeostasis, vascular tone, ACTH release and circadian regulation.
• Dysregulated vasopressin receptor activity underlies nephrogenic diabetes insipidus, hyponatraemia, autosomal dominant polycystic kidney disease and heart failure.
• Vasopressin receptor antagonists (vaptans) are established pharmacological tools and therapeutic agents for these conditions.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal dissection of receptor subtype-specific functions.
Description
Vasopressin receptor activity (GO:0005000) is the molecular function by which a cell binds the neurohypophyseal hormone vasopressin (arginine vasopressin, AVP) and converts that binding event into an intracellular signal. The term is defined in QuickGO as combining with vasopressin to initiate a change in cell activity, and it is classified under molecular_function. Receptors carrying this activity are G-protein-coupled receptors (GPCRs) that mediate diverse physiological responses, including antidiuresis, vasoconstriction, adrenocorticotropin release and modulation of circadian rhythms. Because vasopressin is a small nonapeptide, its receptors provide a tractable system for studying peptide hormone recognition, GPCR activation and subtype-selective pharmacology. For researchers, GO:0005000 is a precise annotation that distinguishes vasopressin receptors from other GPCRs and from vasopressin-metabolizing enzymes. The term encompasses the V1a, V1b and V2 receptor subtypes, which differ in tissue distribution, G-protein coupling and downstream effectors. Mutations in the V2 receptor gene (AVPR2) cause nephrogenic diabetes insipidus, and V2 receptor antagonists are used to treat hyponatraemia and are under investigation in autosomal dominant polycystic kidney disease. Consequently, accurate annotation of vasopressin receptor activity is essential for interpreting genetic, pharmacological and physiological data. This article integrates the QuickGO definition with verified PubMed literature to describe the mechanism, key genes, disease links and experimental methods relevant to GO:0005000. It is intended for researchers who need a concise, citable overview of vasopressin receptor biology and for those designing CRISPR-based models to study this function.
vasopressin receptor activity At A Glance
| GO ID | GO:0005000 |
|---|---|
| GO term | vasopressin receptor activity |
| Ontology | molecular_function |
| Synonym | vasopressin activated calcium mobilizing receptor activity |
| Major function | Binding of vasopressin to initiate intracellular signaling |
| Receptor subtypes | V1a (AVPR1A), V1b (AVPR1B), V2 (AVPR2) |
| Primary ligands | Arginine vasopressin (AVP), desmopressin, synthetic analogs |
| G-protein coupling | Gq/11 for V1a/V1b; Gs for V2 |
| Key tissues | Kidney collecting duct, vascular smooth muscle, pituitary, brain |
What Is GO:0005000?
In plain terms, GO:0005000 describes the activity of a receptor protein that specifically binds vasopressin and, as a result of that binding, triggers a change inside the cell. The QuickGO definition states: Combining with vasopressin to initiate a change in cell activity. This molecular function is attributed to the vasopressin receptor family, which includes V1a, V1b and V2 subtypes, all of which are GPCRs. The synonym vasopressin activated calcium mobilizing receptor activity reflects the fact that some subtypes, particularly V1a and V1b, couple to Gq/11 and mobilize intracellular calcium. The term does not describe the downstream signaling cascade itself but rather the initial recognition and transduction event at the receptor.
Why Is vasopressin receptor activity Important in Cell Biology?
Vasopressin receptor activity is a linchpin of systemic water balance, cardiovascular tone and neuroendocrine stress responses. Its dysfunction directly causes or contributes to nephrogenic diabetes insipidus, the syndrome of inappropriate antidiuresis (SIADH), hyponatraemia, autosomal dominant polycystic kidney disease (ADPKD) and heart failure progression. Pharmacological modulation of these receptors with vaptans is already clinically approved for hyponatraemia and is being explored in ADPKD and heart failure, making GO:0005000 a high-value target for drug discovery. In neuroscience, vasopressin receptor signaling influences circadian rhythms and social behaviors, linking this molecular function to complex behavioral phenotypes.
• Regulates renal water reabsorption through V2 receptor-mediated aquaporin-2 trafficking.
• Controls vascular smooth muscle contraction and blood pressure via V1a receptors.
• Modulates adrenocorticotropin (ACTH) secretion through V1b receptors in the pituitary.
• Influences circadian locomotor activity and clock gene expression in the suprachiasmatic nucleus.
• Mutations in AVPR2 cause X-linked nephrogenic diabetes insipidus.
• V2 receptor antagonists (vaptans) are used to treat hyponatraemia and are studied in ADPKD.
• V1a receptor antagonists are investigated for heart failure and cardiovascular disease.
• V1b receptor variations have been associated with empathy-related behaviors in humans.
• Provides a model system for understanding peptide hormone recognition by GPCRs.
• Serves as a target for patent-protected therapeutic agents in multiple disease areas.
Molecular Mechanism of vasopressin receptor activity
Ligand binding and receptor activation
In simple terms: Vasopressin docks into a pocket on the receptor, causing the receptor to change shape and become active.
Vasopressin receptor activity begins with high-affinity binding of the nonapeptide vasopressin to the extracellular loops and transmembrane helices of the receptor. This binding stabilizes an active conformation that promotes guanine nucleotide exchange on the associated heterotrimeric G-protein. The V2 receptor (AVPR2) couples primarily to Gs, activating adenylyl cyclase and raising cAMP, whereas V1a and V1b receptors couple to Gq/11, activating phospholipase C and mobilizing intracellular calcium. The synonym vasopressin activated calcium mobilizing receptor activity specifically highlights the calcium-mobilizing property of V1-type receptors.
G-protein coupling and second messenger generation
In simple terms: Once active, the receptor turns on G-proteins, which then produce small messenger molecules inside the cell.
Activated V2 receptors stimulate Gs, leading to adenylyl cyclase activation and increased cAMP levels; cAMP then activates protein kinase A (PKA), which phosphorylates aquaporin-2 and promotes its insertion into the apical membrane of renal collecting duct cells. V1a and V1b receptors stimulate Gq/11, leading to phospholipase C beta activation, inositol trisphosphate (IP3) production and calcium release from intracellular stores. These second messengers propagate the signal to downstream effectors, including kinases and ion channels, thereby initiating the cellular response.
Receptor desensitization and internalization
In simple terms: After signaling, the receptor is turned off and pulled inside the cell to prevent overstimulation.
Prolonged exposure to vasopressin leads to phosphorylation of the receptor by G-protein-coupled receptor kinases (GRKs), followed by recruitment of beta-arrestins, which uncouple the receptor from G-proteins and target it for internalization via clathrin-coated pits. This desensitization process is critical for preventing excessive signaling and is a point of regulation for receptor activity. Mutations that impair internalization or recycling can lead to altered receptor availability and have been implicated in disease states such as nephrogenic diabetes insipidus.
Subtype-specific signaling and tissue context
In simple terms: Different receptor subtypes trigger different responses depending on the tissue they are in.
The three major vasopressin receptor subtypes exhibit distinct signaling profiles and tissue distributions. V2 receptors are predominantly expressed in the kidney collecting duct, where they mediate antidiuresis. V1a receptors are found in vascular smooth muscle, liver and brain, where they mediate vasoconstriction and other effects. V1b receptors are expressed in the anterior pituitary and brain, where they regulate ACTH secretion and behavioral responses. This subtype diversity allows a single hormone, vasopressin, to elicit a wide range of physiological outcomes through GO:0005000 activity.
Key Genes Involved in GO:0005000 vasopressin receptor activity
The following genes encode proteins that carry or directly regulate vasopressin receptor activity (GO:0005000).
| Gene | Major Role | Research Relevance |
|---|---|---|
| AVPR1A | V1a receptor; couples to Gq/11; mediates vasoconstriction and circadian effects | Target for cardiovascular and behavioral studies |
| AVPR1B | V1b receptor; couples to Gq/11; regulates ACTH release and social behavior | Linked to empathy-related phenotypes |
| AVPR2 | V2 receptor; couples to Gs; mediates renal water reabsorption | Mutations cause nephrogenic diabetes insipidus |
| AQP2 | Aquaporin-2 water channel; downstream effector of V2 signaling | Key marker of V2 receptor activity in kidney |
| GNAS | Gs alpha subunit; transduces V2 receptor signals | Essential for cAMP-mediated V2 effects |
| GNAQ | Gq alpha subunit; transduces V1a/V1b receptor signals | Mediates calcium mobilization |
| PLCB1 | Phospholipase C beta 1; produces IP3 and DAG downstream of Gq | Effector of V1 receptor signaling |
| PRKACA | Protein kinase A catalytic subunit; phosphorylates AQP2 | Mediates V2-induced water permeability |
| ARRB1 | Beta-arrestin 1; desensitizes and internalizes receptors | Regulates receptor recycling |
| GRK2 | G-protein-coupled receptor kinase 2; phosphorylates activated receptors | Involved in desensitization |
| AVP | Vasopressin precursor; ligand for all receptor subtypes | Central to water balance and stress responses |
| CREB1 | Transcription factor activated by cAMP; regulates AQP2 expression | Downstream of V2 receptor |
| ADCY6 | Adenylyl cyclase 6; produces cAMP downstream of Gs | Effector of V2 signaling in kidney |
| CALM1 | Calmodulin; modulates calcium signaling downstream of V1 receptors | Regulates calcium-dependent responses |
| ITPR1 | IP3 receptor; releases calcium from ER | Mediates V1 receptor calcium signaling |
| RHOA | Small GTPase; regulates cytoskeletal changes downstream of V1a | Contributes to vascular smooth muscle contraction |
| MAPK1 | ERK2; activated by vasopressin in some cell types | Links receptor activity to proliferation |
| NFATC1 | Transcription factor activated by calcium; downstream of V1 receptors | Mediates gene expression changes |
How Is vasopressin receptor activity Regulated?
Vasopressin receptor activity is regulated at multiple levels. Receptor abundance is controlled by transcriptional mechanisms, and in the kidney, chronic vasopressin exposure can alter AVPR2 expression. Post-translational regulation includes phosphorylation by GRKs, which promotes beta-arrestin recruitment and desensitization. Receptor internalization and recycling determine the number of receptors available at the cell surface. Additionally, the activity of downstream effectors such as adenylyl cyclase and phospholipase C can be modulated by other signaling pathways, providing crosstalk. In disease states such as heart failure, elevated vasopressin levels can lead to receptor desensitization and altered responsiveness. Pharmacological antagonists can block receptor activity and are used to modulate these pathways therapeutically.
vasopressin receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AVPR2 | Nephrogenic diabetes insipidus | Knockout or point-mutation in renal cell lines; patient-derived iPSCs |
| AVPR2 | ADPKD cyst growth | Knockout in MDCK cyst model; overexpression in renal epithelial cells |
| AVPR1A | Heart failure and vasoconstriction | Knockout in vascular smooth muscle cells; overexpression in cardiomyocytes |
| AVPR1B | Social behavior and empathy | Knockout in mouse models; point mutation in human cell lines |
| AVPR2 | Hyponatraemia / SIADH | Knockout in collecting duct cells; reporter assays for cAMP |
Nephrogenic diabetes insipidus and AVPR2 mutations
Loss-of-function mutations in AVPR2, which encodes the V2 vasopressin receptor, cause X-linked nephrogenic diabetes insipidus, a disorder characterized by the kidney's inability to concentrate urine despite adequate vasopressin levels. These mutations can impair ligand binding, G-protein coupling, or receptor trafficking, leading to reduced cAMP production and defective aquaporin-2 membrane insertion. Research into these mutations has provided insights into GPCR structure-function relationships and has guided the development of pharmacological chaperones.
Hyponatraemia and syndrome of inappropriate antidiuresis
Excessive vasopressin receptor activity, particularly V2 receptor signaling, can lead to hyponatraemia through water retention. This occurs in the syndrome of inappropriate antidiuresis (SIADH), which is often associated with cancer and other conditions. Vasopressin receptor antagonists (vaptans) that block V2 receptors are used to treat hyponatraemia by promoting aquaresis. The involvement of vasopressin receptors in cancer-associated hyponatraemia highlights the clinical importance of GO:0005000.
Autosomal dominant polycystic kidney disease (ADPKD)
In ADPKD, vasopressin V2 receptor activity promotes cAMP accumulation in cyst-lining epithelial cells, stimulating cell proliferation and fluid secretion that drive cyst growth. The V2 receptor antagonist tolvaptan has been shown to slow disease progression in clinical trials and is approved for ADPKD in some regions. This makes V2 receptor activity a validated therapeutic target and a focus for research into disease mechanisms.
Heart failure and cardiovascular disease
V1a receptors mediate vasoconstriction and can contribute to increased vascular resistance in heart failure. Vasopressin receptor antagonists, particularly V1a antagonists, have been investigated for their potential to improve hemodynamics in heart failure, although clinical outcomes have been mixed. The role of V1a receptor activity in cardiovascular pathophysiology continues to be an active area of research.
From vasopressin receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of AVPR2 abolish vasopressin-induced cAMP signaling? | CRISPR knockout in renal collecting duct cells |
| How does a specific AVPR2 mutation affect receptor trafficking? | Point mutation knock-in in HEK293 cells |
| Can a tagged V2 receptor be used to track internalization? | Knock-in of fluorescent tag (e.g., GFP) at AVPR2 locus |
| Does overexpression of AVPR1A enhance vasoconstriction? | Overexpression in vascular smooth muscle cells |
| What is the role of AVPR1B in ACTH release? | Knockout in pituitary cell lines |
| Can CRISPR screening identify modifiers of V2 receptor signaling? | Genome-wide CRISPR library screening in renal cells |
How to Study the vasopressin receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| cAMP GloSensor assay | Intracellular cAMP levels | V2 receptor activity and drug screening |
| Calcium imaging | Intracellular calcium flux | V1a/V1b receptor activation |
| Radioligand binding | Receptor affinity and density | Subtype characterization and pharmacology |
| Immunofluorescence | Receptor localization and trafficking | Mutant receptor studies |
| Western blot | Protein expression and phosphorylation | Downstream signaling analysis |
| qRT-PCR | mRNA expression of receptors and effectors | Gene expression profiling |
| CRISPR knockout screen | Gene essentiality for receptor signaling | Discovery of novel regulators |
| Beta-arrestin recruitment assay | Receptor desensitization and internalization | Functional characterization of mutants |
cAMP and calcium signaling assays
Vasopressin receptor activity can be measured by quantifying second messenger production. For V2 receptors, cAMP levels are typically measured using luminescent or fluorescent reporters (e.g., GloSensor) or by ELISA. For V1a/V1b receptors, intracellular calcium mobilization is assessed using calcium-sensitive dyes (e.g., Fluo-4) or genetically encoded calcium indicators. These assays are essential for determining receptor function and for screening agonists and antagonists.
Receptor binding assays
Radioligand binding assays using tritiated vasopressin or iodinated analogs allow determination of receptor affinity, density and subtype specificity. These methods are valuable for characterizing mutant receptors and for pharmacological profiling of novel compounds.
Immunofluorescence and live-cell imaging
To study receptor localization and trafficking, immunofluorescence or live-cell imaging of tagged receptors (e.g., GFP or HA) can be used. This reveals whether receptors are properly delivered to the plasma membrane or retained intracellularly, which is important for understanding disease-causing mutations.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate vasopressin receptor signaling or downstream responses. Such screens are powerful for uncovering novel modifiers of GO:0005000 activity and for identifying potential therapeutic targets.
How CRISPR Can Be Used to Study GO:0005000 vasopressin receptor activity
Knockout
CRISPR knockout of AVPR2, AVPR1A or AVPR1B in cell lines such as HEK293 or renal collecting duct cells can completely abolish receptor activity, providing a clean background to study subtype-specific signaling. Knockout models are also useful for validating the specificity of pharmacological agonists and antagonists.
Point Mutation
Introducing disease-associated point mutations (e.g., in AVPR2) via CRISPR base editing or homology-directed repair allows researchers to dissect how specific amino acid changes affect ligand binding, G-protein coupling or trafficking. Such models are invaluable for understanding genotype-phenotype relationships in nephrogenic diabetes insipidus.
Knock-in
Knock-in of epitope tags (e.g., HA, FLAG) or fluorescent proteins (e.g., GFP) at the endogenous AVPR2 locus enables real-time tracking of receptor expression, localization and internalization without overexpression artifacts. This approach preserves native regulatory elements and provides physiological relevance.
Overexpression
Overexpression of wild-type or mutant vasopressin receptors in cell lines can amplify signaling for biochemical assays and is useful for studying gain-of-function mutations. However, overexpression may saturate signaling pathways, so results should be interpreted with caution and validated in endogenous systems.
How EDITGENE Supports vasopressin receptor activity Research
Researchers studying vasopressin receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor signaling, trafficking or downstream responses. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for vasopressin receptor activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| NLRP6 Knockout HCT 116 Cell Line | EDJ-KQ21 | Human | 171389 | Details Get a Quote |
| AVPR1B Knockout HEK293 Cell Line | EDJ-KQ945 | Human | 553 | Details Get a Quote |
| NLRP6 Knockout HEK293 Cell Line | EDJ-KQ1132 | Human | 171389 | Details Get a Quote |
| OXTR Knockout HEK293 Cell Line | EDJ-KQ1595 | Human | 5021 | Details Get a Quote |
| AVPR1A Knockout HEK293 Cell Line | EDJ-KQ1596 | Human | 552 | Details Get a Quote |
| AVPR2 Knockout HEK293 Cell Line | EDJ-KQ1721 | Human | 554 | Details Get a Quote |
| INPP5K Knockout HEK293 Cell Line | EDJ-KQ13108 | Human | 51763 | Details Get a Quote |
| NPSR1 Knockout HEK293 Cell Line | EDJ-KQ14485 | Human | 387129 | Details Get a Quote |
| INPP5K Knockout A-549 Cell Line | EDJ-KQ24929 | Human | 51763 | Details Get a Quote |
| OXTR Knockout A-549 Cell Line | EDJ-KQ21279 | Human | 5021 | Details Get a Quote |
| OXTR Knockout HCT 116 Cell Line | EDJ-KQ21280 | Human | 5021 | Details Get a Quote |
| OXTR Knockout HeLa Cell Line | EDJ-KQ21281 | Human | 5021 | Details Get a Quote |
| INPP5K Knockout HCT 116 Cell Line | EDJ-KQ43683 | Human | 51763 | Details Get a Quote |
| INPP5K Knockout HeLa Cell Line | EDJ-KQ43684 | Human | 51763 | Details Get a Quote |
| AVPR1A Knockout HeLa Cell Line | EDJ-KQ52699 | Human | 552 | Details Get a Quote |
Displaying Records 1 To 15 Of 28 Records
Frequently Asked Questions About vasopressin receptor activity
What is vasopressin receptor activity?
Vasopressin receptor activity (GO:0005000) is the molecular function of binding vasopressin and initiating a change in cell activity, typically through G-protein-coupled signaling.
What genes are involved in vasopressin receptor activity?
The main genes are AVPR1A (V1a receptor), AVPR1B (V1b receptor) and AVPR2 (V2 receptor), which encode the three major vasopressin receptor subtypes.
What is the GO ID for vasopressin receptor activity?
The Gene Ontology ID is GO:0005000.
What diseases are associated with vasopressin receptor mutations?
Mutations in AVPR2 cause nephrogenic diabetes insipidus, and altered receptor activity is implicated in hyponatraemia, ADPKD and heart failure.
How can I study vasopressin receptor activity in the lab?
Common methods include cAMP and calcium signaling assays, radioligand binding, immunofluorescence and CRISPR-based genetic screens.
What are vasopressin receptor antagonists?
Vasopressin receptor antagonists, also called vaptans, are drugs that block receptor activity and are used to treat hyponatraemia and studied in ADPKD and heart failure.
Which receptor subtype is targeted in ADPKD?
The V2 receptor (AVPR2) is the primary target in ADPKD, and the antagonist tolvaptan is approved for this condition in some countries.
How does vasopressin receptor signaling regulate water balance?
V2 receptor activation in the kidney increases cAMP, leading to aquaporin-2 insertion into the collecting duct membrane and increased water reabsorption.
Can CRISPR be used to create vasopressin receptor knockout models?
Yes, CRISPR knockout of AVPR1A, AVPR1B or AVPR2 is a standard approach to study loss of receptor function in cell lines.
What is the role of V1b receptors in behavior?
V1b receptors in the brain have been associated with social behaviors, including empathy, in human genetic studies.
Conclusion
Vasopressin receptor activity (GO:0005000) is a fundamental molecular function that mediates the diverse actions of vasopressin in water balance, cardiovascular regulation, neuroendocrine signaling and behavior. Its clinical relevance is underscored by diseases such as nephrogenic diabetes insipidus, hyponatraemia, ADPKD and heart failure, where receptor dysfunction or overactivity plays a key role. The availability of pharmacological antagonists and the power of CRISPR-based models make this an exciting area for both basic and translational research. By integrating the QuickGO definition with verified literature, this article provides a concise resource for researchers studying vasopressin receptor activity. EDITGENE's CRISPR services can further accelerate discovery by enabling precise genetic manipulation of receptor genes and their regulators.
References
- 1. Makita N et al.. 2020. V2 vasopressin receptor mutations.. Vitam Horm 113:79-99 PMID: 32138955
- 2. Baska F et al.. 2023. Vasopressin receptor antagonists: a patent summary (2018-2022).. Expert Opin Ther Pat 33(5):385-395 PMID: 37226495
- 3. Naldi L et al.. 2026. Hyponatraemia and cancer.. Best Pract Res Clin Endocrinol Metab 40(1):102066 PMID: 41233268
- 4. Birnbaumer M. 2000. Vasopressin receptors.. Trends Endocrinol Metab 11(10):406-10 PMID: 11091117
- 5. Torres VE. 2015. Vasopressin receptor antagonists, heart failure, and polycystic kidney disease.. Annu Rev Med 66:195-210 PMID: 25493947
- 6. Bittman EL. 2009. Vasopressin: more than just an output of the circadian pacemaker? Focus on "Vasopressin receptor V1a regulates circadian rhythms of locomotor activity and expression of clock-controlled genes in the suprachiasmatic nuclei".. Am J Physiol Regul Integr Comp Physiol 296(3):R821-3 PMID: 19109364
- 7. Streefkerk JO et al.. 2006. Vasopressin receptor antagonists: pharmacological tools and potential therapeutic agents.. Auton Autacoid Pharmacol 26(2):141-8 PMID: 16553642
- 8. Shima T et al.. 2022. Physical activity associates empathy in Japanese young adults with specific gene variations of oxytocin receptor and vasopressin V1B receptor.. Physiol Behav 255:113930 PMID: 35905808
